$CANFAug 17, 2026, 11:00 AMAI processed
Namodenoson boosts gemcitabine chemo activity in pancreatic cancer (preclinical), backing Phase IIb combo trial
AI Summary
Can‐Fite reported preclinical data showing namodenoson increased cleaved caspase‐3 and enhanced apoptosis when combined with gemcitabine in pancreatic cancer models, suggesting the drug weakens tumor survival pathways and makes chemo more effective. The company says these mechanistic results support its planned randomized Phase IIb testing namodenoson with gemcitabine plus nab‐paclitaxel in advanced pancreatic adenocarcinoma; Phase 2a pancreatic results were accepted for presentation at ESMO 2026.
Positives
- Preclinical combo of namodenoson + gemcitabine increased cleaved caspase‑3, indicating higher tumor-cell apoptosis versus chemo alone
- Data provide mechanistic rationale and specifically support a planned randomized Phase IIb combining namodenoson with gemcitabine and nab‑paclitaxel
- Phase 2a pancreatic clinical results have been accepted for presentation at ESMO 2026
Negatives
- Findings are preclinical only; no clinical efficacy data for the combination were reported
- Phase IIb is planned but not yet underway or completed, so human proof of benefit remains unproven
- Press release did not provide quantitative in vivo efficacy or safety metrics for the combo